Download PDFPDF

Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Infilximab in Ocular Behçet's Disease

    Dear Editor

    We read with great interest the letter of Triolo et al[1]. In the discussion section of the article the authors mentioned that this is the first report of the treatment of ocular BD with anticytokine specific treatment.

    In July 2001, Sfikakis et al.[2] reported on a series of five patients with relapsing Behçet's panuveitis, treated with a single infusion of infliximab at the immed...

    Show More
    Conflict of Interest:
    None declared.